高原地区创伤性脑损伤患者血清降钙素原水平与病情严重程度及预后的关系
该前瞻性队列研究纳入西宁第三人民医院(海拔2260米)与格尔木市人民医院(海拔2780米)重症医学科2018年5月至2022年9月收治的120例创伤性脑损伤患者,按入院GCS评分分为轻度(13-15分,52例)、重度(9-12分,40例)、危重(3-8分,28例)三组,于入院第1、3、5、7天测定血清PCT。重度与危重组PCT在第3天达峰且显著高于轻度组,随访至2022年10月30日死亡28例(死亡率23.33%),死亡组第3天PCT显著高于存活组。Cox回归显示入院时IL-6、外周血WBC、脑脊液PCT及第1、3、5、7天血清PCT均为随访期死亡的独立危险因素;各时点血清PCT预测死亡的AUC均>0.8,入院第3天最佳截断值1.88 μg/L,敏感度78.6%、特异度88.0%。
要点
- 高原地区创伤性脑损伤患者入院第3天血清PCT达峰,重度组3.53±0.68 μg/L、危重组4.47±0.63 μg/L,均显著高于轻度组0.40±0.14 μg/L(均P<0.05)。
- 死亡组入院第3天血清PCT为4.11±0.62 μg/L,显著高于存活组0.52±0.13 μg/L(P<0.01),存活组PCT随入院时间持续下降。
- 入院第3天血清PCT预测随访期死亡的AUC为0.800(95%CI 0.701-0.899),最佳截断值1.88 μg/L,敏感度78.6%、特异度88.0%。
- 入院第1、3、5、7天血清PCT均为随访期死亡的独立危险因素,HR分别为6.776(95%CI 1.844-24.906)、1.840(95%CI 1.069-3.165)、3.447(95%CI 1.284-9.254)、6.666(95%CI 1.214-36.618)(均P<0.05)。
- 作者认为血清PCT>3 μg/L可能与重症相关,>1.88 μg/L可预测不良预后,动态观察血清PCT变化对高原地区创伤性脑损伤患者的病情严重程度和预后有良好评估价值。
适用人群与场景
- 西宁第三人民医院(海拔2260米)与格尔木市人民医院(海拔2780米)重症医学科2018年5月至2022年9月收治的创伤性脑损伤患者,共120例。
- 按入院GCS评分分组:轻度损伤组(GCS 13-15分)52例、重度损伤组(GCS 9-12分)40例、危重损伤组(GCS 3-8分)28例;所有患者均接受积极治疗。
诊断标准与关键阈值
- 按入院格拉斯哥昏迷评分(GCS)分度:轻度损伤GCS 13-15分,重度损伤GCS 9-12分,危重损伤GCS 3-8分。
- 入院第3天血清PCT最佳截断值1.88 μg/L用于预测随访期死亡,敏感度78.6%、特异度88.0%。
处置流程与药物剂量
- 所有患者均接受积极治疗。
- 采用化学发光免疫法测定入院第1、3、5、7天血清PCT水平,动态观察其变化。
研究设计与关键结果
- 前瞻性队列研究,纳入120例高原地区创伤性脑损伤患者;轻度组血清PCT随入院时间持续下降,重度组与危重组于入院第3天达峰,分别为3.53±0.68 μg/L、4.47±0.63 μg/L,均显著高于轻度组0.40±0.14 μg/L(均P<0.05),此后逐渐下降,但第7天仍显著高于轻度组。
- Kendall tau-b相关分析显示入院第1、3、5、7天血清PCT与病情严重程度呈显著正相关(r值分别为0.801、0.808、0.766、0.528,均P<0.01)。
- 截至2022年10月30日,120例中存活92例、死亡28例,死亡率23.33%;与存活组比较,死亡组入院时GCS评分、血清IL-6、外周血WBC、脑脊液PCT均显著升高[GCS评分:5.20±0.82 vs. 4.35±0.93,IL-6(ng/L):1.63±0.45 vs. 0.95±0.27,外周血WBC(×10⁹/L):14.31±2.03 vs. 11.95±1.98,脑脊液PCT(μg/L):11.30±1.21 vs. 3.02±0.68,均P<0.01]。
- 存活组血清PCT随入院时间持续下降;死亡组入院第3天达峰为4.11±0.62 μg/L,显著高于存活组0.52±0.13 μg/L(P<0.01),此后逐渐下降,但第7天仍显著高于存活组。
- Cox回归显示入院时血清IL-6(HR=17.347,95%CI 5.874-51.232)、外周血WBC(HR=1.383,95%CI 1.125-1.700)、脑脊液PCT(HR=1.952,95%CI 1.535-2.482)及入院第1、3、5、7天血清PCT[HR(95%CI)分别为6.776(1.844-24.906)、1.840(1.069-3.165)、3.447(1.284-9.254)、6.666(1.214-36.618)]均为随访期死亡的独立危险因素(均P<0.05)。
- ROC曲线显示入院第1、3、5、7天血清PCT预测随访期死亡的AUC均>0.8[AUC(95%CI)分别为0.898(0.821-0.975)、0.800(0.701-0.899)、0.899(0.828-0.970)、0.865(0.773-0.958)],预测价值理想。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为血清PCT>3 μg/L可能与重症相关,>1.88 μg/L可预测不良预后,动态观察血清PCT变化对高原地区创伤性脑损伤患者的病情严重程度和预后有良好评估价值。
- 对高原地区创伤性脑损伤患者,入院第1、3、5、7天动态监测血清PCT可为病情严重程度与随访期死亡风险评估提供参考。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To analyze the changes rule of serum procalcitonin (PCT) levels in patients with traumatic brain injury in plateau areas, and to evaluate its value in assessing the severity and prognosis of the patients.
METHODS: A prospective cohort study was conducted. The patients with traumatic brain injury admitted to the critical care medicine departments of Xining Third People's Hospital (at an altitude of 2 260 metres) and Golmud City People's Hospital (at an altitude of 2 780 metres) from May 2018 to September 2022 were enrolled. According to the Glasgow coma scale (GCS) score at admission, the patients were divided into mild injury group (GCS score 13-15), severe injury group (GCS score 9-12), and critical injury group (GCS score 3-8). All patients received active treatment. Chemiluminescence immunoassay was used to measure the serum PCT levels of patients on the 1st, 3rd, 5th, and 7th day of admission. The Kendall tau-b correlation method was used to analyze the correlation between serum PCT levels at different time points and the severity of the disease. The patients were followed up until October 30, 2022. The prognosis of the patients was collected. The baseline data of patients with different prognosis were compared. The Cox regression method was used to analyze the relationship between baseline data, serum PCT levels at different time points and prognosis. Receiver operator characteristic curve (ROC curve) was drawn to analyze the predictive value of serum PCT levels at different time points for death during follow-up.
RESULTS: Finally, a total of 120 patients with traumatic brain injury were enrolled, including 52 cases in the mild injury group, 40 cases in the severe injury group, and 28 cases in the critical injury group. The serum PCT levels of patients in the mild injury group showed a continuous downward trend with the prolongation of admission time. The serum PCT levels in the severe injury and critical injury groups reached their peak at 3 days after admission, and were significantly higher than those in the mild injury group (μg/L: 3.53±0.68, 4.47±0.63 vs. 0.40±0.14, both P < 0.05), gradually decreasing thereafter, but still significantly higher than the mild injured group at 7 days. Kendall tau-b correlation analysis showed that there was a significant positive correlation between serum PCT levels on days 1, 3, 5, and 7 of admission and the severity of disease (r value was 0.801, 0.808, 0.766, 0.528, respectively, all P < 0.01). As of October 30, 2022, 92 out of 120 patients with traumatic brain injury survived and 28 died, with a mortality of 23.33%. Compared with the survival group, the GCS score, serum interleukin-6 (IL-6) levels, white blood cell count (WBC) in peripheral blood, and PCT levels in cerebrospinal fluid at admission in the death group were significantly increased [GCS score: 5.20±0.82 vs. 4.35±0.93, IL-6 (ng/L): 1.63±0.45 vs. 0.95±0.27, blood WBC (×109/L): 14.31±2.03 vs. 11.95±1.98, PCT in cerebrospinal fluid (μg/L): 11.30±1.21 vs. 3.02±0.68, all P < 0.01]. The serum PCT levels of patients in the survival group showed a continuous downward trend with prolonged admission time. The serum PCT level in the death group peaked at 3 days after admission and was significantly higher than that in the survival group (μg/L: 4.11±0.62 vs. 0.52±0.13, P < 0.01), gradually decreasing thereafter, but still significantly higher than the survival group at 7 days. Cox regression analysis showed that serum IL-6 levels [hazard ratio (HR) = 17.347, 95% confidence interval (95%CI) was 5.874-51.232], WBC in peripheral blood (HR = 1.383, 95%CI was 1.125-1.700), PCT levels in cerebrospinal fluid (HR = 1.952, 95%CI was 1.535-2.482) at admission and serum PCT levels on admission days 1, 3, 5, and 7 [HR (95%CI) was 6.776 (1.844-24.906), 1.840 (1.069-3.165), 3.447 (1.284-9.254), and 6.666 (1.214-36.618), respectively] were independent risk factors for death during follow-up in patients with traumatic brain injury (all P < 0.05). ROC curve analysis showed that the AUC of serum PCT levels on days 1, 3, 5, and 7 for predicting death during follow-up in patients with traumatic brain injury was all > 0.8 [AUC (95%CI) was 0.898 (0.821-0.975), 0.800 (0.701-0.899), 0.899 (0.828-0.970), 0.865 (0.773-0.958), respectively], indicating ideal predictive value. The optimal cut-off value for serum PCT level at 3 days of admission was 1.88 μg/L, with the sensitivity of 78.6% and specificity of 88.0% for predicting death during follow-up.
CONCLUSIONS: Abnormal expression of serum PCT levels in patients with traumatic brain injury on the 3rd day of admission was found. The serum PCT levels greater than 3 μg/L may be related to severe illness. The serum PCT levels greater than 1.88 μg/L can predict the poor prognosis of patients. Dynamic observation of changes in serum PCT levels has good evaluation value for the severity and prognosis of patients with traumatic brain injury in plateau areas.
参考来源
- Zhang L, Zhang F, Bai H, et al. [Relationship between serum procalcitonin level and severity and prognosis in patients with traumatic brain injury in plateau areas]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 38404273. doi:10.3760/cma.j.cn121430-20230425-00317
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。